SAB Biotherapeutics, Inc. Common Stock
Symbol: SABS (NASDAQ)
2.77
▼ (-7.67%) -0.230
Company Description:
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Key Stats
- Today's Open: $2.9
- Today's High: $2.9
- Today's Low: $2.77
- Today's Volume: 1.40K
- Yesterday Close: $3
- Yesterday High: $3.07
- Yesterday Low: $2.76
- Yesterday Volume: 514.68K
- Last Min Volume: 1
- Last Min High: $2.77
- Last Min Low: $2.77
- Last Min VWAP: $2.77
Company Profile
- Name: SAB Biotherapeutics, Inc. Common Stock
- Website: https://www.sab.bio
- Listed Date: 2021-10-22
- Location: MIAMI BEACH, FL
- Market Status: Active
- CIK Number: 0001833214
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $31.23M
- Round Lot: 100
- Outstanding Shares: 10.41M
- Asset Type: CS
RECENT FILINGS FOR SABS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-03 | SCHEDULE 13G | View |
| 2025-10-03 | SCHEDULE 13D | View |
| 2025-10-03 | SCHEDULE 13G | View |
| 2025-10-01 | 4 | View |
| 2025-10-01 | 4 | View |
| 2025-09-30 | EFFECT | View |
| 2025-09-30 | 8-K | View |
| 2025-09-26 | 8-K | View |
| 2025-09-22 | S-3/A | View |
| 2025-09-22 | 4 | View |
| 2025-09-02 | S-3 | View |
| 2025-08-29 | DEF 14A | View |
| 2025-08-28 | 4 | View |
| 2025-08-28 | 4 | View |
| 2025-08-28 | 4 | View |
| 2025-08-28 | 4 | View |
| 2025-08-28 | 4 | View |
| 2025-08-19 | PRE 14A | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-05 | D | View |
Latest News on SABS